You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
|
|---|---|
| Published in |
Journal of Clinical Oncology, August 2009
|
| DOI | 10.1200/jco.2009.23.6802 |
| Pubmed ID | |
| Authors |
Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz, Angela Dispenzieri, Francis Buadi, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, David Dingli, Robert A. Kyle, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, Joseph R. Mikhael, A. Keith Stewart, Kristina Laumann, Jacob B. Allred, Sumithra J. Mandrekar, S. Vincent Rajkumar |
| Abstract |
Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma. Pomalidomide is a new IMiD with high in vitro potency. We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Kenya | 1 | 20% |
| India | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 40% |
| Scientists | 2 | 40% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 2 | 1% |
| Spain | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 144 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 22 | 15% |
| Student > Ph. D. Student | 22 | 15% |
| Researcher | 20 | 14% |
| Student > Bachelor | 15 | 10% |
| Student > Postgraduate | 12 | 8% |
| Other | 32 | 22% |
| Unknown | 25 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 64 | 43% |
| Agricultural and Biological Sciences | 13 | 9% |
| Biochemistry, Genetics and Molecular Biology | 9 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Economics, Econometrics and Finance | 4 | 3% |
| Other | 21 | 14% |
| Unknown | 30 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2024.
All research outputs
#2,182,046
of 25,371,288 outputs
Outputs from Journal of Clinical Oncology
#5,187
of 22,043 outputs
Outputs of similar age
#6,814
of 102,011 outputs
Outputs of similar age from Journal of Clinical Oncology
#22
of 179 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,043 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 102,011 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 179 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.